Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.
U.S. stocks broke their three-day losing streak today, with the S&P 500 gaining 0.8%. The narrower, price-weighted Dow Jones Industrial Average (DJINDICES: ^DJI ) gained 0.7%, closing above 16,000 for the first time.
Last week, I highlighted�three reasons why Warren Buffett bought ExxonMobil (NYSE: XOM ) for Berkshire Hathaway's (NYSE: BRK-B ) equity portfolio. (He did so in size, too -- the position was valued at $3.4 billion at the end of the third quarter.) This week, short-seller Jim Chanos, who famously bet against failed energy company Enron, offered a few reasons of his own -- for steering clear of the shares, characterizing ExxonMobil as a "value trap." Is Mr. Chanos right? Did the Oracle of Omaha just make a monumental mistake?
At the Reuters Global Investment Outlook on Tuesday, Chanos described his negative thesis regarding the energy supermajor's business and its stock:
Top 10 Oil Companies To Invest In Right Now: Onconova Therapeutics Inc (ONTX)
Onconova Therapeutics, Inc. (Onconova), incorporated on December 22, 1998, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways, which promote cancer. It has three clinical-stage product candidates and six preclinical programs. Its preclinical pipeline includes six programs, which target kinases, cellular metabolism or division.
Rigosertib
Rigosertib, the Company�� product candidate, is being tested in a range of ongoing Phase-II and Phase-III clinical trials. The Company is conducting a pivotal phase-III trial of rigosertib under a Special Protocol Assessment (SPA), from the United States Food and Drug Administration (FDA), for higher risk myelodysplastic syndromes (MDS). The Company is also evaluating rigosertib in a Phase-III trial for metastatic pancreatic cancer, in two Phase-II trials for transfusion-dependent lower risk MDS, and in a Phase-II trial for head and neck cancers. Rigosertib has been granted orphan drug status for MDS in both the United States and Europe, as well as orphan drug status for pancreatic cancer in the United States. Baxter Healthcare SA (Baxter), a subsidiary of Baxter International Inc., has commercialization rights for rigosertib in Europe and SymBio Pharmaceuticals Limited (SymBio), has commercialization rights in Japan and Korea. Rigosertib is an inhibitor of two cellular signaling pathways: phosphoinositide 3-kinase (PI3K), and polo-like kinase (PLK), both of which are frequently over-active in cancer cells. By inhibiting the PI3K pathway in cancer cells, rigosertib promotes tumor cell apoptosis, or programmed cell death. It is testing both intravenous and oral formulations of rigosertib, referred to as rigosertib IV and rigosertib Oral, in clinical trials.
ON 013105
The Company�� clinical-stage product candidate, ON 013105, is i! n a Phase I trial in patients with relapsed or refractory lymphoma, including an aggressive form of non-Hodgkin's lymphoma identified as mantle cell lymphoma (MCL), and acute lymphoid leukemia (ALL). ON 013105 suppresses the accumulation of cyclin D1 in cancer cells.
Recilisib
The Company�� clinical-stage product candidate, recilisib, is being developed in collaboration with the United States Department of Defense (DoD), for acute radiation syndromes (ARS). The Company has completed four Phase-I trials to evaluate the safety and pharmacokinetics of recilisib in healthy human adult subjects using both subcutaneous and oral formulations, referred to as recilisib SC and recilisib Oral.
Preclinical Programs
The Company�� ON 1231320 is a specific inhibitor of Polo-like Kinase 2 (PLK2), and in preclinical studies, it induced mitotic arrest and reduced tumor burden in mice injected subcutaneously with colon tumor and triple-negative breast cancer cells. The Company�� ON 123300 inhibits the activity of two kinases, cyclin-dependent kinase 4 (CDK4), and AMP-activated protein kinase 5 (ARK5). Its ON 108600 is a dual inhibitor of two growth-regulatory kinases. Cyclin-dependent kinase 9 is over expressed in several cancers, including leukemias and lymphomas. Casein kinase 2 is overexpressed in a range of tumor types. ON 044580 inhibits mutant forms of the two target kinases, including Janus Kinase 2 (JAK2) and imatinib-resistant Bcr-Abl Kinase (Bcr-Abl). Its ON 24 compounds cause tubulin to depolymerize, inducing mitotic arrest in cultured tumor cell lines. Its ON 146040 inhibits the growth of a range of blood cancer cell lines, including Burkitt's lymphoma, MCL, multiple myeloma and chronic myeloid leukemia.
The Company competes with Eisai Inc., Celgene Corporation, Genentech, Inc., Cell Therapeutics, Inc., Cyclacel Pharmaceuticals, Inc., Telik, Inc., Spectrum Pharmaceuticals, Inc., Astex, Array BioPharma Inc., Astellas Pharma, Inc., Threshold! Pharmace! uticals, Inc., Pharmacyclics Inc., Soligenix, Inc., Cellerant Therapeutics, Inc. and Cleveland BioLabs, Inc.
Advisors' Opinion:- [By Roberto Pedone]
Onconova Therapeutics (ONTX), a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. This stock closed up 2.5% to $5.15 in Thursday's trading session.
Thursday's Range: $4.97-$5.19
52-Week Range: $4.10-$31.13
Thursday's Volume: 132,000
Three-Month Average Volume: 216,102From a technical perspective, ONTX trended modestly higher here with lighter-than-average volume. This stock has been uptrending over the last few weeks, with shares moving higher from its low of $4.10 to its recent high of $5.52. During that uptrend, shares of ONTX have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ONTX within range of triggering a near-term breakout trade. That trade will hit if ONTX manages to take out Thursday's intraday high of $5.19 to some more key overhead resistance at $5.52 with high volume.
Traders should now look for long-biased trades in ONTX as long as it's trending above some near-term support levels at $4.80 or at $4.50 and then once it sustains a move or close above those breakout levels with volume that hits near or above 216,102 shares. If that breakout gets underway soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $5.83 to $6.27. Any high-volume move above those levels will then give ONTX a chance to tag $7.
- [By gurujx]
Onconova Therapeutics Inc (ONTX) Reached the 3-year Low of $4.18
The prices of Onconova Therapeutics Inc (ONTX) shares have declined to close to the 3-year low of $4.18, which is 86.8% off the 3-year high of $31.13.
- [By Roberto Pedone]
One under-$10 clinical-state biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Onconova Therapeutics (ONTX), which focuses on discovering and developing small molecule drug candidates to treat cancer. This stock has been destroyed by the short-sellers so far in 2014, with shares off sharply by 56%.
If you glance at the chart for Onconova Therapeutics, you'll notice that this stock has been trending sideways and consolidating right below its 50-day moving average for the last few weeks. This consolidation pattern is occurring right after shares of ONTX recently spiked sharply higher from its low of $4.10 to its high of $5.52 a share. Shares of ONTX are now trending within range of breaking out of that consolidation pattern and potentially heading higher.
Traders should now look for long-biased trades in ONTX if it manages to break out above its 50-day moving average of $5.09 a share and then once it takes out some more key overhead resistance levels at $5.24 to $5.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 203,756 shares. If that breakout triggers soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $6.27 to $7 a share.
Traders can look to buy ONTX off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.75 to right around $4.50 a share. One can also buy ONTX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Best Healthcare Technology Stocks To Watch For 2014: Rex Energy Corporation(REXX)
Rex Energy Corporation operates as an independent oil and gas company in the Appalachian Basin and the Illinois Basin. It focuses on the Marcellus Shale drilling projects, and Utica Shale and Upper Devonian Shale exploration activities in the Appalachian Basin. The company also holds interests in the Lawrence Field ASP Flood project, which is an oil recovery project located in Lawrence County, Illinois. As of December 31, 2011, it operated approximately 2,117 wells, including approximately 517 disposal and injection wells. The company had estimated proved reserves of 366.2 billions of cubic feet equivalent. Rex Energy Corporation was founded in 2007 and is headquartered in State College, Pennsylvania.
Advisors' Opinion:- [By The Energy Report]
Onshore, my favorite play is the Utica Shale, in which my top plays are Gulfport Energy Corp. (GPOR) and Rex Energy Corp. (REXX). Both companies have highly economic acreage, solid balance sheets and industry-leading production growth. I also like Rex Energy for its likely production upside. Another one of my favorite plays is the Eagle Ford Shale, in which my top plays are Penn Virginia Corp. (PVA) and Sanchez Energy Corp. (SN). Both have core acreage in the region, improving operating results and experienced management. Another favorite name of mine is Midstates Petroleum Co. Inc. (MPO). The company has assets in three solid plays and a management team with a long successful track record. Those are my favorite names at this time.
- [By Matt DiLallo]
These infrastructure additions are important for Gulfport Energy� (NASDAQ: GPOR ) �which is pouring nearly all of its resources into developing the Utica's assets. If its wells provide the type of production it is expecting, this infrastructure build-out will prove critical to Gulfport's ability to deliver its product to market. The additions are also important for Rex Energy (NASDAQ: REXX ) which is investing more than 30% of its more than $255 million 2013 capital budget to develop its acreage in the Utica.
- [By Arjun Sreekumar]
Infrastructure additions also bode well for Gulfport Energy (NASDAQ: GPOR ) , a company highly levered to the play. In fact, Gulfport is plowing the majority of its capital budget toward developing its Utica acreage, with quite impressive well results thus far. Improved infrastructure should also provide a boost to Rex Energy (NASDAQ: REXX ) , which is allocating nearly a third of its roughly $255 million capital budget for the year toward developing its assets in the Utica.
- [By Matt DiLallo]
The company has also shifted some of its attention to next-door neighbor Ohio's Utica Shale. It's not the only Marcellus driller to look to the higher profit potential in the liquids-rich Utica. Smaller drillers like Rex Energy (NASDAQ: REXX ) are also looking west to the Utica in an effort to grow liquids production. The company reported positive results at three recently drilled wells at its Warrior South project. While all this attention is great for the Utica, Pennsylvania would rather have drillers investing that drilling capital within its borders to add more jobs and tax revenue. �
Best Healthcare Technology Stocks To Watch For 2014: Boral Ltd (BLD)
Boral Limited (Boral), is engaged in the manufacture and supply of building and construction materials in Australia, the United States and Asia. The Company�� operating segments include Construction Materials & Cement, Building Products, Boral Gypsum, and Boral USA. The Construction Materials & Cement is engaged in quarries, concrete, asphalt, transport, landfill, property, cement and concrete placing. The Building Products segment is engaged in Australian bricks, roof tiles, masonry, timber products and windows. The Boral Gypsum involves Australian and Asian plasterboard. The Boral USA is engaged in Bricks, cultured stone, roof tiles, fly ash, concrete and quarries. Advisors' Opinion:- [By Eric Lam]
Ballard Power (BLD), which designs and manufactures hydrogen fuel cells, slumped 15 percent to C$1.42, the biggest decline since March. The company yesterday said it will sell about 9 million units at $1.40 a unit for proceeds of about $12.6 million. The cash generated will be used to fund working capital, support growth and general corporate purposes, the company said.
Best Healthcare Technology Stocks To Watch For 2014: France Telecom S.A.(FTE)
France Telecom provides fixed telephony and mobile telecommunications, data transmission, Internet and multimedia, and other value-added services to consumers, businesses, and telecommunications operators. It also offers personal and home communication services, business network services, international carriers and shared services, and integration and outsourcing services for communication applications. The company operates in France, Spain, Poland, the United Kingdom, and internationally. France Telecom was founded in 1990 and is based in Paris, France.
Advisors' Opinion:- [By Sofia Horta e Costa]
Barclays Plc (BARC) fell to a one-month low as Sumitomo Mitsui Banking Corp. sold a stake in the lender. Fiat SpA lost 6.5 percent as Chrysler Group LLC went in for a vehicle recall. France Telecom SA (FTE) rose after its Orange Business Services unit won a five-year deal to deploy a private network for Heineken NV. Johnson Matthey Plc (JMAT) jumped to its highest price in at least 23 years after posting full-year profit that beat estimates.
Best Healthcare Technology Stocks To Watch For 2014: Sprint Corp (S&LS)
Sprint Corporation, incorporated on May 10, 2012, offers a range of wireless and wireline communications services to consumers, businesses and government users. On July 10, 2013, the Company, SoftBank Corp. and Sprint Nextel Corporation (Sprint Nextel) completed the merger. In the Merger, Sprint Corporation was merged into Sprint Nextel, New Sprint became the parent company of Sprint Nextel, with Sprint Nextel becoming its direct wholly owned subsidiary, and Sprint Nextel changed its name to Sprint Communications, Inc.
The Company develops, engineers and deploys technologies, including the first wireless fourth generation (4G) service from a national carrier in the United States; offering mobile data services, prepaid brands, including Virgin Mobile USA, Boost Mobile, and Assurance Wireless; instant national and international push-to-talk capabilities, and a global Tier 1 Internet Service. The Company also offers unlimited data services.
Advisors' Opinion:- [By Holly LaFon]
Since Wilmers & Co. took over M&T Bank in 1983 the bank has acquired 23 banks and Savings and Loans (S&Ls) ��expanding from a single state to seven ��and assets have grown from $2 billion to $110 billion. M&T's branch count has grown from 60 to over 870. The bank currently boasts a customer base of over 2 million retail household customers and nearly 220,000 commercial customers.
Best Healthcare Technology Stocks To Watch For 2014: Interleukin Genetics Inc (ILIU.PK)
Interleukin Genetics, Inc., incorporated on March 28, 2000, is a personalized health company, which develops genetic tests to provide information to manage health and specific health risks. The Company�� business focuses on personalized health, by providing genetic tests with clinical value. Its tests are made available through marketing partners or directly to end users. The Company's primary business focus and strategy is to continue the Company's commercialization efforts with its PST genetic test. In addition, the Company plans to continue to develop and sells tests for its own business needs under the Inherent Health brand.
The Company's genetic tests that are being commercialized includes PST is a genetic test, which analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease; Weight Management Genetic Test determines whether a low fat, low carbohydrate or balanced diet may normal or vigorous exercise, which is needed to lose existing body fat; Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis; Heart Health Genetic Test is designed to identify genetic predisposition to excess inflammation, which is a risk factor for heart attack, and Wellness Select Genetic Test allows buyers to purchase any combination of Inherent Health genetic tests at a discounted price. The Company is also focusing its genetic test development efforts on the development of an Osteoarthritis, or OA, genetic test to identify individuals at increased risk for severe OA.
Genetic Test for Risk of Periodontal Disease
PST is a genetic test that analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease. The PST genetic test identifies specific polymorphisms (genetic variations) in genes that! regulate the production of interleukin cytokines.Interleukin-1 (IL-1) is well-established as one of the critical regulators of periodontal disease, and studies in non-human primates have shown that drugs specifically blocking IL-1 alone or IL-1 plus TNFa reduces tissue destruction even when the bacterial challenge is not reduced.
Inherent Health Brand of Genetic Tests
The Company's Weight Management Genetic Test helps take the guesswork out of finding an effective diet and exercise solution by revealing actionable steps to achieve weight goals based on genetics. The test provides new information beyond traditional assessments, so that nutritional intake and fitness routines can be tailored for improved, sustainable results. This test identifies five SNPs in four human genes: fatty acid binding protein 2 (FABP2); adrenergic receptor beta 2 (ADRB2 two variations); adrenergic receptor beta 3 (ADRB3); and peroxisome proliferator-activated receptor gamma (PPAR- ). These markers are involved in certain physiological pathways relating to body weight. Certain patterns of markers are associated with differential response to certain diet and exercise regimens.
The Company has conducted a number of studies that demonstrate a gene-diet interaction based on the multi-locus patterns . In the original study, 311 overweight/obese (body mass index, 27-40 kg/m2), nondiabetic, premenopausal, generally healthy women were randomly assigned for 12 months to either the Atkins-like ( low carbohydrate), Zone-like (low carbohydrate), LEARN-like (balanced), or Ornish-like (low fat) diets for the primary purpose of losing weight. The data collected in that study included dietary intake assessment (three unannounced 24-hour recalls for each time point administered by a dietitian and analyzed using NDS-R, University of Minnesota), anthropometric measures including weight, and related physiological variables, all collected at baseline, two, six, and 12 months.
Bone Health Genetic T! est
The Company's Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis. Although it typically starts later in life, early intervention can help prevent osteoporosis. Preventive measures can reduce the risk for bone loss and fractures, which in the case of vertebral fractures leads to a hunched over appearance. The test identifies a SNP in each of three genes involved in processes that affect bone; estrogen receptor alpha (ER1 Xba1), vitamin D receptor (VDR), and interleukin-1 (IL-1). Certain patterns of variations are associated with increased risk of spine fracture and/or low bone mineral density. The test can be used as an aid to making diet, exercise, and other lifestyle choices to maintain and improve bone health.
Nutritional Needs Genetics Test
The Company's Nutritional Needs Genetics Test is designed to identify DNA variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress. Individuals with certain variations in these genes may be at increased risk for ineffective utilization of B-vitamins and potential for cell damage caused by oxidative stress, both of which can in some cases lead to increased risk for certain diseases. The test identifies the presence or absence of human genotypic markers methylenetetrahydrofolate reductase (MTHFR) and transcobalamin II (TCN2) involved in vitamin B metabolism and markers superoxide dismutase 2 (SOD2), glutathione S-transferase 1 deletions (GSTM1), paraoxonase 1 (PON1), X-ray repair cross complementing group 1 (XRCC1) in response to oxidative stress. Certain variations are associated with less efficient B-vitamin metabolism or reduced activity of endogenous anti-oxidant systems. The test may be used to aid individuals in deciding whether to supplement their diet with B vitamins and/or antioxidants.
Genetic Test Pipeline
The Company is focusing! its gene! tic test development efforts on programs, including Osteoarthritis Genetic Test. OA is the common adult joint disease, increasing in frequency and severity in all aging populations. The estimated U.S. prevalence is 20-40 million patients or five times that of rheumatoid arthritis. The Company's OA program plans to investigate whether interleukin gene variations together with several other inflammatory gene variations is associated with the occurrence of multi-joint OA for the development of a genetic risk assessment test.
Advisors' Opinion:- [By Brian Marckx]
Interleukin Genetics, Inc. (ILIU.PK) develops genetic tests focused on personal health. Through applied genetics research and scientific collaborations, the company has made significant progress in understanding how genetic make-up can affect an individual's predisposition and risk of suffering from certain diseases. Interleukin's research has specifically focused on a form of genetic variation called single nucleotide polymorphisms (SNP) and how it can have an impact on a person's health. The company has applied this knowledge in the development of genetic tests focused on areas such as weight management, cardiovascular health and periodontal disease. Interleukin sells its Inherent Health line of tests, which launched in 2009, to the consumer market and maintains a CLIA-certified lab at its headquarters in Waltham, Massachusetts, where consumers send test samples for processing.
Best Healthcare Technology Stocks To Watch For 2014: Hess Corporation (HES)
Hess Corporation, together with its subsidiaries, operates as an independent energy company worldwide. It operates in two segments, Exploration and Production (E&P), and Marketing and Refining (M&R). The E&P segment explores for, develops, produces, purchases, transports, and sells crude oil and natural gas. This segment conducts exploration and production activities principally in Algeria, Australia, Azerbaijan, Brunei, China, Denmark, Egypt, Equatorial Guinea, France, Ghana, Indonesia, the Kurdistan region of Iraq, Libya, Malaysia, Norway, Peru, the Russian Federation, Thailand, the United Kingdom, and the United States. The M&R segment purchases, markets, and trades in refined petroleum products, natural gas, and electricity. This segment serves motoring public, wholesale distributors, industrial and commercial users, other petroleum companies, governmental agencies, and public utilities. It also operates terminals and retail gasoline stations, which include convenience stores located on the East Coast of the United States. As of December 31, 2012, the company operated 1,361 HESS gasoline stations in New York, New Jersey, Pennsylvania, Florida, Massachusetts, North Carolina, and South Carolina. Hess Corporation was founded in 1920 and is headquartered in New York, New York.
Advisors' Opinion:- [By Maxx Chatsko]
The easy winners
Hess (NYSE: HES ) was one of my favorite companies on the list. Despite it having a growing presence in the Bakken at the time, investors sent shares down after a temporary setback in production. The impact on sales was minimal and the long-term growth opportunity remained intact. By all accounts Hess was a great company caught in traffic. The good news is that rush hour doesn't last forever. Shares were trading at about $45 per share when I wrote the blog post linked to above, but have recovered nicely since.
No comments:
Post a Comment